Participants received either four stem cell injections two weeks apart or five weekly hyaluronate injections, with outcomes tracked for 12 months.
The Indian biotech company previously published a Phase 3 RCT comparing its therapy to placebo in 146 KOA patients.
YiPSCELL's lead candidate delivers three-dimensional cartilage organoids derived from induced pluripotent stem cells through an injection into the joint cavity.
The ongoing US and EU study is testing NVD003, an autologous cell-based therapy, in patients with a rare, difficult-to-treat pediatric bone condition.
In mice with collagen-induced arthritis, several ERNA-201 candidates lowered disease severity versus untreated controls, while the company shifts near-term spending to ERNA-101’s planned ovarian cancer trial filing.
Nonclinical findings showed the investigational therapy reduced inflammation, tissue damage and pain sensitivity while promoting cellular repair, supporting its ongoing Phase 1 trial.
The Korean biotech company reported improved pain, joint function, and MRI-based structural measures versus placebo at 24 weeks, with no drug-related serious adverse events.
Kolon TissueGene’s phase 3 trial found its osteoarthritis therapy did not improve knee pain or function versus placebo, leaving the biotech to await results from a second late-stage study before deciding the program’s future.
And it begins... the Korean biotech company whose product, Cartistem, has been approved in Korea since 2012, passed Phase 3 in Japan, and is now entering the West.
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
This marks the first stem cell therapy for KOA to reach Phase III in China. The race is heating up...
The Living Knee project is hoping to replace traditional knee replacements, expected to begin Phase 1 trials around 2028.
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
The 4 US and 1 European patents cover the design and manufacturing of the company's placental therapies. The company is targeting various applications across orthopedics, urology, and wound care.
The Korean biotech company published the multicenter Phase 1 results in Nature, with 24-week follow-up MRI data that look promising as they continue development.
The companies are working to bring jellyfish-derived Collagen Type Zero to North America, aiming to advance wound care and regenerative medicine with a sustainable alternative to mammalian collagen.
The Phase 1 cord blood-derived stem cell therapy for sacroiliac joint-related lower back pain showed an encouraging early safety profile and symptom improvement, supporting plans to begin Phase 2 later this year.
Researchers in Colorado are advancing injectable and biomaterial-based therapies that, in animal studies, restored damaged cartilage and bone by triggering the body’s own repair processes, potentially offering a minimally invasive alternative to pain management or joint replacement.
Mesoblast said its 300-patient placebo-controlled Phase 3 study of rexlemestrocel-L for chronic low back pain remains on track, with top-line data expected in mid-2027 to support a planned FDA filing for the non-opioid cell therapy.
Gallant said its pilot study found that intravenous stem cell therapy significantly improved pain and quality of life in cats with osteoarthritis versus placebo, supporting a faster regulatory route as the company pursues a disease-modifying treatment for an underserved condition.
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell therapies. By sourcing mesenchymal stem cells from uterine tissue collected during routine spays, it has built an off-the-shelf platform with consistent, high-yield cells and FDA-aligned manufacturing, with a potential first FDA…
The San Diego non-profit has received a $12.7 million grant to advance scaffold-free tissue engineering research aimed at repairing knee cartilage and bone damage.
Exo-Top and BioXtek have signed a non-binding letter of intent to explore a partnership focused on GMP manufacturing, clinical supply, and potential commercialization of bone marrow-derived mesenchymal stem cell exosomes.
A proposed class action alleges QC Kinetix and related defendants failed to disclose that certain regenerative pain treatments were not FDA-approved and used misleading financing offers to sell them.
They've completed enrollment of 99 patients across 15 U.S. sites in its Phase 2 trial evaluating BRTX-100, a mesenchymal stem cell therapy for chronic lumbar disc disease.